Macrocyclic c hepatitis serine protease inhibitors

The present invention provides a compound of formula I, II or III: Here, W is a substituted or unsubstituted heterocyclic ring system, compound, or their pharmaceutically acceptable salts, esters, or prodrugs. This compound, serine proteases, in particular inhibiting hepatitis C virus (HCV) NS3-NS4A protease activity. Accordingly, the compounds of the present invention is therefore interfere with the life cycle of the hepatitis C virus, it is also useful as antiviral agents. The present invention is for administration to a patient, further suffering from HCV infection, a pharmaceutical composition comprising said compound. The present invention also relates to a method of treating an HCV infection in a patient by administering a compound comprising a pharmaceutical composition of the present invention.